BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17147244)

  • 21. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
    Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
    Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
    Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
    Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method.
    Shi Y; Li LZ; Sun JZ; Zhang T; Peng J; Xu CG
    Ann Hematol; 2008 Jan; 87(1):35-41. PubMed ID: 17846772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
    Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
    Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L; Savranskaya L; Sweatman TW
    Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript].
    Liu HX; Cao XY; Tong CR; Wu T; Wang T; Fan QZ; Wu P; Zhang X; Cai P; Zhu P
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):220-3. PubMed ID: 19552835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
    Andreasen RB; Olsson L
    J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
    Gery S; Tanosaki S; Hofmann WK; Koppel A; Koeffler HP
    Oncogene; 2005 Feb; 24(9):1589-97. PubMed ID: 15674331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.